The registry is open to recruiting new centers. The RENIS II project covers the monitoring of patients with renal cell carcinoma (RCC). The sponsor and professional guarantor of the register is the Czech Oncological Society ČLS JEP. RENIS II is a multicenter, non-interventional, observational, prospective study of patients with renal cell carcinoma (stage I-IV).

Data registration has a central methodological guidance and pursues not only scientific goals. Parametric evaluation of the course of treatment will enable the introduction of methodological standards, control of entry criteria for starting treatment and methodically correct evaluation of the treatment response.

Ongoing data evaluation and feedback, which is thus obtained for physicians and healthcare management, meets the basic criteria of evidence-based medicine. All patients rights are fully preserved and data collection is in accordance with GDPR.

The selection of patients who have an entry in the registry is within the competence of the attending physician. Indications for diagnostic and treatment procedures, prescribing, monitoring, and all other treatment decisions are not dependent on this project and are the sole responsibility of the attending physician.


Primary goal

The primary objective of the study is to monitor the total number of patients diagnosed with RCC in the Czech Republic.

Secondary goals
  • Evaluation of the effectiveness of the treatment being monitored and the treatment regimens used
  • Analysis of patient survival in relation to the observed clinical factors
  • Evaluation of the safety of the treatment being monitored


Professional Warranty
  • Czech Oncological Society ČLS JEP
  • The guarantor of the registry is doc. MUDr. Alexandr Poprach, Ph.D.
  • Evaluation of the safety of the treatment being monitored
Project Management
  • The Institute of Biostatistics and Analyses, s.r.o., spin-off of Masaryk University, provides management and other service activities of this project
  • MVDr. Renata Rouhová, project manager Ing. Petr Brabec, Ph.D., Managing Director